The current status of lymph node dissection in the treatment of papillary thyroid cancer. A literature review

Clinica Terapeutica

Volumn 164, Issue SUPPL.4, 2013, Pages

  Conzo, Giovanni ^a   Docimo, G ^a   Mauriello, C ^a   Gambardella, C ^a   Esposito, D ^a   Cavallo, F ^a   Tartaglia, E ^a   Napolitano, S ^a   Santini, L ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Active iodine ablation; Lymph node neck dissection; Papillary thyroid cancer; Radio; Routine central lymph node dissection; Total thyroidectomy

Indexed keywords

CERVICAL LYMPH NODE; HUMAN; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MEDLINE; MICROMETASTASIS; NECK DISSECTION; PAPILLARY THYROID CANCER; PRACTICE GUIDELINE; RECURRENT CANCER; REVIEW; THYROID CANCER; TREATMENT INDICATION; CARCINOMA; LYMPH NODE METASTASIS; PATHOLOGY; THYROID NEOPLASMS; CANCER SURGERY;

CARCINOMA; HUMANS; LYMPHATIC METASTASIS; NECK DISSECTION; THYROID NEOPLASMS;

EID: 84885730326     PISSN: 00099074     EISSN: 19726007     Source Type: Journal    
DOI: 10.7417/CT.2013.1599     Document Type: Review

References (38)

1. Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501-11
2. Trimboli P, Ulisse S, Graziano FM, et al. Trend in thyroid carcinoma size, age at diagnosis and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 2006; 16:1151-5
3. White ML, Gauger PG, Doherty GM, et al. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007; 31:895-904
4. Shen WT, Ogawa L, Ruan D, et al. Central neck lymph node dissection for papillary thyroid cancer: the reliability of surgeon judgment in predicting which patients will benefit. Surgery 2010; 148:398-403
5. Henry JF, Gramatica L, Denizot A, et al. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. Langenbecks Arch Surg 1998; 383:167-9
6. Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid 2009; 19:683-9
7. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-214
8. Pezzolla A, Docimo G, Ruggiero R, et al. Incidental thyroid carcinoma: a multicentric experience. Rec Prog Med 2010;101:194-8
9. Conzo G, Circelli L, Pasquali D, et al. Lessons to be learned from the clinical management of a MEN 2A patient bearing a novel 634/640/700 triple mutation of the RET protooncogene. Clin Endocrinol 2012; 77(6):934-6
10. Di Vizio D, Insabato L, Conzo G, et al. Sarcomatoid carcinoma of the colon: a case report with literature review. Tumori 2001; 87:431-5
11. Passler C, Scheuba C, Prager G, et al. Prognostic factors of papillary and follicular thyroid cancers: differences in an iodine-replete endemic goiter region. Endocr-Relat Cancer 2004; 11:131-9
12. Falvo L, Catania A, D'Andrea V, et al. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg 2005; 241:640-6
13. Conzo G., Troncone G, Docimo G, et al. Cytologically undetermined follicular lesions: surgical procedures and histological outcome in 472 cases. Ann Ital Chir 2013; 84:251-6
14. Cantisani V, Ulisse S, Guaitoli E, et al. Q-elastography in the presurgical diagnosis of thyroid nodules with indeterminate cytology. PLoS One 2012; 7:e50725
15. Troncone G, Volante M, Iaccarino A, et al. Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurtle cell neoplasms. Cancer Cytopathol 2009; 117:522-9
16. Papale F, Cafiero G, Grimaldi A, et al. Galectin-3 expression in thyroid fine needle cytology (t-FNAC) uncertain cases: validation of molecular markers and technology innovation. J Cell Physiol 2013; 228:968-74
17. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91:313-9
18. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery 2008; 144:980-7
19. Pasquali D, Santoro A, Bufo P, et al. Upregulation of Endocrine Gland-Derived Vascular Endothelial Growth factor in Papillary thyroid Cancers Displaying Infiltrative Patterns, Lymph Node Metastases, and Braf mutation. Thyroid 2011; 21:391-9
20. Baldini E, Sorrenti S, Di Gioia C, et al. Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology? BMC Clin Pathol 2013; 13:7
21. Baldini E, Sorrenti S, Catania A, et al. Diagnostic utility of thyroglobulin measurement in the fine needle aspirates from cervical lymph nodes: a case report. G Chir 2012; 33:387-91
22. Bonnet S, Hartl D, Leboulleux S, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2cm: implications for radioiodine treatment. J Clin Endrocrinol and Metab 2009; 94:1162-7
23. Ulisse S, Baldini E, Sorrenti S, et al. High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J Clin Endocrinol Metab 2011; 96:504-8
24. Ulisse S, Baldini E, Sorrenti S, et al. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol 2012; 77:780-6
25. Cirocchi R, Boselli C, Guarino S, et al. Total thyroidectomy with ultrasonic dissector for cancer: multicentric experience.World J Surg Oncol 2012; 10:70
26. Calò PG, Pisano G, Medas F, et al. The use of the harmonic scalpel in thyroid surgery. Our experience. Ann Ital Chir 2012; 3:7-12
27. Docimo G, Ruggiero R, Subitosi A, et al. Ultrasound scalpel thyroidectomy: prospective randomized study. Ann It Chir 2012 (in press)
28. Conzo G, Stanzione F, Palazzo A, et al. La linfectomia nel cancro differenziato della tiroide. Chir Ital 2009; 16:539-44
29. Noguchi S, Murakami N, Yamashita H, et al. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 1998; 133:276-80
30. Cooper DS, Doherty GM, Haugen BR, et al. Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce. Thyroid 2006; 16:109-42
31. Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. The Laryngoscope 2009; 119:1135-9
32. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007; 31:895-904
33. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroidcarcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154:787-803
34. Carling T, Carty SE, Ciarleglio MM, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid 2012; 22:237-44
35. Carling T, Long WD 3rd, Udelsman R. Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer. Curr Opin Oncol 2010; 22:30-4
36. Conzo G, Pasquali D, Bellastella G, et al. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. Endocrine 2013 Jan 19 (in press)
37. Conzo G, Docimo G, Ruggiero R, et al. Surgical treatment of papillary thyroid carcinoma without lymph nodal involvement. G. Chir 2012; 33:339-42
38. De Bellis A, Conzo G, Cennamo G, et al. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 2012; 41:320-6